Omeros is a commercial-stage biopharmaceutical company. Co. is focused on discovering, developing and commercializing small-molecule and protein therapeutics for larger-market as well as orphan indications targeting immunologic diseases. Co.'s drug candidate narsoplimab is the subject of a biologics license application pending before the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Co. has various late-stage clinical development programs in its pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A nephropathy, atypical hemolytic uremic syndrome and COVID-19. The OMER stock yearly return is shown above.
The yearly return on the OMER stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OMER annual return calculation with any dividends reinvested as applicable (on ex-dates).
|